Showing results (1-10 of 415) with videos related to
Sort By:
Pageof 42
Clinical and Experimental Dermatology|November 18, 2003
Etanercept-induced systemic lupus erythematosusV J Swale, C M Perrett, C P Denton, et al.Clinical and Experimental Dermatology|February 24, 2005
Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximabV J Swale, M Saha, N Kapur, et al.Bailliere'S Best Practice & Research. Clinical Rheumatology|July 6, 2000
Scleroderma and related disorders: therapeutic aspectsC P Denton, C M BlackCurrent Rheumatology Reports|December 21, 2000
Novel therapeutic strategies in sclerodermaC P Denton, C M BlackAnnals of the Rheumatic Diseases|June 24, 2006
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsC P Denton, M Humbert, L Rubin, et al.British Journal of Rheumatology|January 1, 1994
Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three casesC P Denton, P Sweny, A Abdulla, et al.Clinical and Experimental Rheumatology|October 3, 2009
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?A Pakozdi, H Wilson, C M Black, et al.The Journal of Investigative Dermatology|March 1, 1997
Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGFC P Denton, S Xu, C M Black, et al.Clinical and Experimental Rheumatology|August 19, 2000
Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot studyC P Denton, K Howell, R J Stratton, et al.Rheumatology (Oxford, England)|April 12, 2007
Using a self-reported functional score to assess disease progression in systemic sclerosisK Serednicka, A E Smyth, C M Black, et al.Pageof 42